Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Elfetabart Drozuntecan · BNT324, DB-1311

Antibody-drug conjugate · Cytotoxic, directed at B7-H3 (CD276) and DNA topoisomerase 1 (TOP1) · developed by BioNTech

Phase 3 Most advanced trial
BNTX Developer
3 Registered trials

What is Elfetabart Drozuntecan?

Elfetabart drozuntecan is an antibody-drug conjugate in which a humanized antibody against B7-H3 (CD276) is linked by a cleavable linker to the topoisomerase-1 inhibitor P1021. After binding B7-H3-expressing tumor cells and internalization, the payload is released and inhibits DNA topoisomerase-1, leading to cell cycle arrest and apoptosis. It is studied in advanced solid tumors and metastatic castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BNT324, DB-1311
Drug type
Antibody-drug conjugate
Targets
B7-H3 (CD276), DNA topoisomerase 1 (TOP1)
Mechanism
Cytotoxic, directed at B7-H3 (CD276) and DNA topoisomerase 1 (TOP1)
Pathways
DNA replication inhibition, cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
BioNTech SE (BNTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
PM33MCX6WE

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07365995 Phase 3 Metastatic Castration-resistant Prostate Cancer Recruiting BNTX
NCT06953089 Phase 2 Solid Tumors Recruiting BNTX
NCT05914116 Phase 1/2 Advanced Solid Tumors Recruiting BNTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsMetastatic Castration-resistant Prostate CancerSolid Tumors

Other drugs acting on CD276 / TOP1

More from BioNTech

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the BNTX page.

Follow BNTX, the company behind Elfetabart Drozuntecan

See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BNTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.